Related Experiment Video
Updated: Jan 19, 2026

Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems
Published on: October 14, 2025
CRISPR-Cas System of a Prevalent Human Gut Bacterium Reveals Hyper-targeting against Phages in a Human Virome Catalog
Paola Soto-Perez1, Jordan E Bisanz1, Joel D Berry1
1Department of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Abstract:
Bacteriophages are abundant within the human gastrointestinal tract, yet their interactions with gut bacteria remain poorly understood, particularly with respect to CRISPR-Cas immunity. Here, we show that the type I-C CRISPR-Cas system in the prevalent gut Actinobacterium Eggerthella lenta is transcribed and sufficient for specific targeting of foreign and chromosomal DNA. Comparative analyses of E. lenta CRISPR-Cas systems across (meta)genomes revealed 2 distinct clades according to cas sequence similarity and spacer content. We assembled a human virome database (HuVirDB), encompassing 1,831 samples enriched for viral DNA, to identify protospacers. This revealed matches for a majority of spacers, a marked increase over other databases, and uncovered "hyper-targeted" phage sequences containing multiple protospacers targeted by several E. lenta strains. Finally, we determined the positional mismatch tolerance of observed spacer-protospacer pairs. This work emphasizes the utility of merging computational and experimental approaches for determining the function and targets of CRISPR-Cas systems.
Related Concept Videos
10:52Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems
11:53Substrate Generation for Endonucleases of CRISPR/Cas Systems
07:32A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System
06:33Production of Human CRISPR-Engineered CAR-T Cells
08:27Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
10:51Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device

